



October 31, 2022

Company name Shin Nippon Biomedical Laboratories, Ltd.
 Representative Representative Chairman, President & CEO
 Ryoichi Nagata
 Listing TSE PRIME : ticker code 2395
 Inquiries Managing Executive Officer, Senior Director,
 Corporate Communications, Toshiyuki Iwata
 TEL +81 3 5565 6216

Notice Regarding Distribution of Interim Dividends from Retained Earnings

Shin Nippon Biomedical Laboratories, Ltd. (hereinafter, “the Company”) announces that it was resolved at its Board of Directors’ meeting today that interim dividends shall be paid from retained earnings to shareholders on the record date of September 30, 2022, as detailed below.

1. Details of interim dividends

	Resolved	Latest forecast (announced on May 6, 2022)	Interim dividends for the previous fiscal year ended March 31, 2022
Record date	September 30, 2022	Same as on the left	September 30, 2021
Dividends per share	¥20.00	Same as on the left	¥0.00
Total dividends	¥832 million	-	-
Effective date	November 30, 2022	-	-
Dividend resource	Retained earnings	-	-

2. Reasons for payment of interim dividends

The Company’s basic policy of profit distributions to shareholders, which is positioned as one of top management priorities, is to achieve the target of 30-40% in payout ratio on a consolidated basis, comprehensively considering Company’s earning capacity and cash flow position. Based on this policy, the Board of Directors decided upon the payment of interim dividends of ¥20.00 per share, which is in line with the latest forecast of dividends for the fiscal year ending March 31, 2023.

(Reference) Breakdown of annual dividends

Record date	Dividends per share (¥: Japanese yen)		
	End of 2 nd quarter	Year-end	Total
Fiscal year ending March 31, 2023	¥20.00 (Actual)	¥20.00 (Forecast)	¥40.00 (Forecast)
Fiscal year ended March 31, 2022	¥0.00 (Actual)	¥40.00 (Actual, including special dividends of ¥10.00)	¥40.00 (Actual, including special dividends of ¥10.00)

(NOTE) Financial forecasts and other statements above are based on information available as of the date of this announcement.

Actual performance may differ substantially due to various factors in the future.